Press Releases

Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina’s proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the...

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1)...

LONDON--(BUSINESS WIRE)--Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory....

February 15, 2023 - Boston, MA – Morphoceuticals Inc., a biotechnology company, announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence....

Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as...

Biotech Leader to Provide Longevity Insights at Annual Conference  Ramsey, Isle of Man – November 1, 2022 – Juvenescence Limited (“Juvenescence”), a life sciences company developing therapies and consumer products...

AgeX Therapeutics announces a manufacturing, marketing and distribution agreement with Pluristyx, an advanced therapy tools and services company, to expand access to clinical-grade human pluripotent stem cells for therapeutic applications.

LyGenesis announces four new peer-reviewed publications highlighting its advancing technology for kidney and liver regeneration.

iTolerance and LyGenesis announced a collaboration to evaluate the potential of iTOL-201 combined with LyGenesis' liver cell therapy (LYG-LIV-100), to enable ectopic livers to be grown without the need or immune...

Juvenescence joins the 200M Fund portfolio in the investment in Chrysea Labs (“Chrysea”), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.

Relation Therapeutics announced today it had raised a $25 million investment and hired a Chief Executive Officer and Chief Technology Officer, enabling Relation to advance therapeutic candidates for diseases with...

Juvenescence & the Buck Institute announce a new joint venture with the formation of Selah Therapeutics Limited (“Selah”). Selah focuses on developing ketone-based therapies to treat heart failure & other...